إسرائيل - الإنجليزية - Ministry of Health

megapharm ltd - flecainide acetate - solution for injection - flecainide acetate 10 mg/ml - flecainide - flecainide - serious sustained life threatening ventricular arrhthymias that have not respoded to other drugs.

سنغافورة - الإنجليزية - HSA (Health Sciences Authority)

dch auriga singapore - prucalopride succinate 1.321mg eqv prucalopride - tablet, film coated - 1mg - prucalopride succinate 1.321mg eqv prucalopride 1mg

سنغافورة - الإنجليزية - HSA (Health Sciences Authority)

dch auriga singapore - prucalopride succinate 2.642mg eqv prucalopride - tablet, film coated - 2mg - prucalopride succinate 2.642mg eqv prucalopride 2mg

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

recordati rare diseases australia pty ltd - ibuprofen, quantity: 5 mg/ml - injection, solution - excipient ingredients: trometamol; sodium hydroxide; sodium chloride; hydrochloric acid; water for injections - pedea is indicated for the treatment of haemodynamically significant patent ductus arteriosus in preterm newborn infants less than 34 weeks of gestational age.

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - palivizumab, quantity: 100 mg - injection, solution - excipient ingredients: histidine; glycine; water for injections - synagis (palivizumab) is indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (rsv) in children at high risk of rsv disease. safety and efficacy were established in children with bronchopulmonary dysplasia (bpd), infants with a history of prematurity (gestational age less than or equal to 35 weeks at birth) and children with haemodynamically significant congenital heart disease (chd). (see clinical trials).

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - palivizumab, quantity: 50 mg - injection, solution - excipient ingredients: histidine; glycine; water for injections - synagis (palivizumab) is indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (rsv) in children at high risk of rsv disease. safety and efficacy were established in children with bronchopulmonary dysplasia (bpd), infants with a history of prematurity (gestational age less than or equal to 35 weeks at birth) and children with haemodynamically significant congenital heart disease (chd). (see clinical trials).

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

life healthcare pty ltd -

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - lisinopril dihydrate (equivalent: lisinopril, qty 20 mg) - tablet, uncoated - excipient ingredients: iron oxide red; maize starch; calcium hydrogen phosphate dihydrate; mannitol; magnesium stearate - hypertension: for treatment of hypertension, lisinopril may be used alone or concomitantly with other classes of antihypertensive agents. sufficient data have not been provided to support the use of lisinopril in severe hypertension or renovascular hypertension. congestive heart failure: for treatment of heart failure, it is recommended that lisinopril be administered with a diuretic. acute myocardial infarction: for treatment of acute myocardial infarction in haemodynamically stable patients, defined as patients who are not in cardiogenic shock and who have a systolic blood pressure greater than 100 mmhg, lisinopril may be initiated within 24 hours of an acute myocardial infarction.

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - lisinopril dihydrate (equivalent: lisinopril, qty 10 mg) - tablet, uncoated - excipient ingredients: magnesium stearate; calcium hydrogen phosphate dihydrate; mannitol; iron oxide red; maize starch - hypertension: for treatment of hypertension, lisinopril may be used alone or concomitantly with other classes of antihypertensive agents. sufficient data have not been provided to support the use of lisinopril in severe hypertension or renovascular hypertension. congestive heart failure: for treatment of heart failure, it is recommended that lisinopril be administered with a diuretic. acute myocardial infarction: for treatment of acute myocardial infarction in haemodynamically stable patients, defined as patients who are not in cardiogenic shock and who have a systolic blood pressure greater than 100 mmhg, lisinopril may be initiated within 24 hours of an acute myocardial infarction.

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - lisinopril dihydrate (equivalent: lisinopril, qty 5 mg) - tablet, uncoated - excipient ingredients: iron oxide red; maize starch; magnesium stearate; calcium hydrogen phosphate dihydrate; mannitol - hypertension: for treatment of hypertension, lisinopril may be used alone or concomitantly with other classes of antihypertensive agents. sufficient data have not been provided to support the use of lisinopril in severe hypertension or renovascular hypertension. congestive heart failure: for treatment of heart failure, it is recommended that lisinopril be administered with a diuretic. acute myocardial infarction: for treatment of acute myocardial infarction in haemodynamically stable patients, defined as patients who are not in cardiogenic shock and who have a systolic blood pressure greater than 100 mmhg, lisinopril may be initiated within 24 hours of an acute myocardial infarction.